RESUMO
The genetic risk of developing type 2 diabetes (T2D) increases in parallel with the proportion of Native American ancestry. Mestizo Mexicans have a 70% Native Amerindian genetic background. The T130I polymorphism in the HNF4A gene has been associated with early-onset T2D in mestizo Mexicans. Thus, the aim of the present study was to evaluate the frequency and relationship of the T130I variant in the HNF4A gene with risk factors for developing T2D in eleven indigenous groups from Mexico. In two groups, all exons of the HNF4A gene were directly sequenced; in the remaining the T130I polymorphism was analyzed by restriction fragment length polymorphism. Ancestry informative markers were assessed to confirm the Amerindian component. An additional analysis of EHH was carried out. Interestingly, HNF4A gene screening revealed only the presence of the T130I polymorphism. The range frequency of the risk allele (T) in the indigenous groups was from 2.7 to 16%. Genotypic frequencies (T130I/I130I) were higher and significantly different from those of all of the populations included in the HapMap Project (P < 0.005). EHH scores suggest a positive selection for T130I polymorphism. Metabolic traits indicate a relationship between the T130I/I130I genotypes with high triglyceride concentrations in the indigenous groups (P < 0.005). These results strongly suggest that the high frequency of the T130I polymorphism and its biological relationship with dysfunction in lipid metabolism in Mexican indigenous groups is a risk factor for the developing of T2D in Mexicans.
Assuntos
Diabetes Mellitus Tipo 2/genética , Predisposição Genética para Doença , Fator 4 Nuclear de Hepatócito/genética , Estudos Transversais , Diabetes Mellitus Tipo 2/etnologia , Etnicidade/genética , Haplótipos , Humanos , México/etnologia , Polimorfismo de Fragmento de Restrição , Polimorfismo de Nucleotídeo ÚnicoRESUMO
Association of type 2 diabetes (T2D) with common variants in HHEX, HNF4α, KCNJ11, PPARγ, CDKN2A/2B, SLC30A8, CDC123/CAMK1D, TCF7L2, ABCA1 and SLC16A11 genes have been reported, mainly in populations of European and Asian ancestry and to a lesser extent in Latin Americans. Thus, we aimed to investigate the contribution of rs1111875 (HHEX), rs1800961 (HNF4α), rs5219 (KCNJ11), rs1801282 (PPARγ), rs10811661 (CDKN2A/2B), rs13266634 (SLC30A8), rs12779790 (CDC123/CAMK1D), rs7903146 (TCF7L2), rs9282541 (ABCA1) and rs13342692 (SLC16A11) polymorphisms in the genetic background of Maya population to associate their susceptibility to develop T2D. This is one of the first studies designed specifically to investigate the inherited component of T2D in the indigenous population of Mexico. SNPs were genotyped by allelic discrimination method in 575 unrelated Maya individuals. Two SNPs rs10811661 and rs928254 were significantly associated with T2D after adjusting for BMI; rs10811661 in a recessive and rs9282541 in a dominant model. Additionally, we found phenotypical alterations associated with genetic variants: HDL to rs9282541 and insulin to rs13342692. In conclusion, these findings support an association of genetic polymorphisms to develop T2D in Maya population.
Assuntos
Transportador 1 de Cassete de Ligação de ATP/genética , Inibidor de Quinase Dependente de Ciclina p15/genética , Inibidor p16 de Quinase Dependente de Ciclina/genética , Diabetes Mellitus Tipo 2/genética , Indígenas Norte-Americanos/genética , Transportadores de Ácidos Monocarboxílicos/genética , Adulto , Índice de Massa Corporal , Diabetes Mellitus Tipo 2/etnologia , Feminino , Estudos de Associação Genética , Predisposição Genética para Doença , Humanos , Indígenas Norte-Americanos/etnologia , Masculino , México/etnologia , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo ÚnicoRESUMO
Previous studies have sought to associate the Pro12Ala variant of the peroxisome proliferator-activated receptor gamma2 (PPARG2) gene with type 2 diabetes, insulin resistance, and obesity, with controversial results. We have determined the Pro12Ala variant frequency in 370 nondiabetic Mexican Mestizo subjects and in five Mexican Amerindian groups and have investigated its possible association with lipid metabolism, insulin serum levels, and obesity in three of these populations. Two independent case-control studies were conducted in 239 nondiabetic individuals: 135 case subjects (BMI > or = 25 kg/m2) and 104 control subjects (BMI < 25 kg/m2). The PPARG2 Ala12 allele frequency was higher in most Amerindian populations (0.17 in Yaquis, 0.16 in Mazahuas, 0.16 in Mayans, and 0.20 in Triquis) than in Asians, African Americans, and Caucasians. The Pro12Ala and Ala12Ala (X12Ala) genotypes were significantly associated with greater BMI in Mexican Mestizos and in two Amerindian groups. X12Ala individuals had a higher risk of overweight or obesity than noncarriers in Mestizos (OR = 3.67; 95% CI, 1.42-9.48; p = 0.007) and in Yaquis plus Mazahuas (OR = 3.21; 95% CI, 1.27-8.11; p = 0.013). Our results provide further support of the association between the PPARG2 Ala12 allele and risk of overweight or obesity in Mestizos and two Amerindian populations from Mexico.
Assuntos
Variação Genética/genética , Genética Populacional/métodos , Genótipo , Indígenas Norte-Americanos/genética , PPAR gama/genética , Adulto , Índice de Massa Corporal , Humanos , México , Pessoa de Meia-Idade , Obesidade/genéticaRESUMO
The short term effects of norethisterone (NET), progesterone (P), estradiol (E2) and dihydrotestosterone (DHT) on the gonadotropin secretion of pituitary cells, from both male and female rats, in primary culture primed with E2 were studied. In female cells, NET only increased the GnRH-induced secretion of LH, while P increased both LH and FSH. Male pituitary cells showed an increased response to GnRH after P pretreatment only if the E2 concentration was augmented. However with the same E2 conditions pretreatment with NET decreased the stimulated LH, but not FSH secretion. Pretreatment with E2 inhibited LH stimulated secretion from pituitary cells of male but not female rats. Furthermore DHT treatment diminished the GnRH response for both LH and FSH in pituitary cells from both sexes. Androgen pretreatment increased basal gonadotropin secretion in male but not in female cells. Basal FSH secretion was increased by NET pretreatment in male cells. This suggests that NET is metabolized by cultured pituitary cells to A-ring reduced compounds during the 4 h incubation period. The formation of NET metabolites, particularly the 3 beta, 5 alpha and 5 alpha-NET might be responsible for the estrogenic and androgenic effects observed when NET was administered to the cultured pituitary cells.
Assuntos
Hormônios Esteroides Gonadais/farmacologia , Gonadotropinas/metabolismo , Noretindrona/farmacologia , Adeno-Hipófise/efeitos dos fármacos , Animais , Células Cultivadas , Di-Hidrotestosterona/farmacologia , Estradiol/farmacologia , Feminino , Hormônio Foliculoestimulante/metabolismo , Hormônio Liberador de Gonadotropina/farmacologia , Hormônio Luteinizante/metabolismo , Masculino , Adeno-Hipófise/metabolismo , Progesterona/farmacologia , Ratos , Ratos Wistar , Caracteres SexuaisRESUMO
Hormonal quantitation has had important developments since Yalow and Berson created the first radioimmunoassay for insulin in 1959. Since then much research has been done to find new non-isotopic methods which offer better levels of sensitivity, specificity and precision than RIA. DELFIA (dissociation enhancement lanthanide fluoroimmunoassay) is a new alternative technology which is a specific time resolved fluoroimmunoassay (TR-FIA) which combines higher purified antigens, monoclonal antibodies in a sandwich type assay with long fluorescence decay time of lanthanide chelates as europium, samarium and terbium used as labels, and a particular time resolving fluorometer for nanoseconds measurements. As part of the validation and introduction of the DELFIA method in our laboratory we made a comparative evaluation of DELFIA and RIA in the quantification of serum luteinizing hormone and follicle stimulating hormone. The data favor the DELFIA method in terms of sensitivity, specificity, volume of sample, half life of reagents, as well as the elimination of radioactive tracers.
Assuntos
Fluorimunoensaio , Hormônio Foliculoestimulante/sangue , Hormônio Luteinizante/sangue , Radioimunoensaio , Estudos de Avaliação como Assunto , Humanos , Reprodutibilidade dos Testes , Sensibilidade e EspecificidadeRESUMO
A pilot study to assess the use of natural hormones in macrocrystalline sustained release system was undertaken in normal menstruating women. Progesterone at a dose of 100 mg in combination with 5 mg estradiol-17 beta aqueous macrocrystalline suspension (3ml) of defined particle size range (100-250 microns) were administered to five female volunteers of reproductive age, on day 5 of their normal menstrual cycles and then every 28 days consecutively for the next two months. Peripheral venous blood samples were obtained from the women three times a week for 60 days after the third injection for the measurement of serum progesterone, estradiol-17 beta, LH and FSH. The menstrual bleeding patterns were closely monitored during the study period. The results obtained indicate that the exogenous hormone administration produces blood levels similar to those observed during the luteal phase of the menstrual cycle. Follicular maturation as assessed by endogenous estradiol rise, above 150 pg/ml, occurred 29.7 days s.d. 6.4 after the injection. Ovulation as measured by progesterone levels above 5 ng/ml was documented 34.4 days s.d. 4.3 after the third injection. The bleeding patterns were regular though initially shorter but these increased progressively towards normal pattern during course of the study. The data suggest that progesterone/estradiol-17 beta combination administered as an aqueous macrocrystalline suspension is capable of producing sustained ovulation inhibition and could be applied in the design of new once-a-month injectable contraceptives.
Assuntos
Anticoncepcionais Femininos/administração & dosagem , Estradiol/administração & dosagem , Ovulação/efeitos dos fármacos , Progesterona/administração & dosagem , Adulto , Preparações de Ação Retardada , Combinação de Medicamentos , Estradiol/sangue , Feminino , Gonadotropinas Hipofisárias/sangue , Humanos , Injeções Intramusculares , Projetos Piloto , Progesterona/sangueRESUMO
To examine the molecular mechanisms involved in the antigonadotropic effects of norethisterone (NET) and two of its A-ring reduced metabolites the 5 alpha-norethisterone (5 alpha-NET) and the 3 beta, 5 alpha-norethisterone (3 beta, 5 alpha-NET) at the neuroendocrine level, a series of experiments were undertaken in adult castrated rats. Animals were primed either with 0.2 mg of tamoxifen (Tam) for 4 consecutive days or 1.0 mg of cyproterone acetate (CPA) for 7 days followed by a single subcutaneous injection of 0.5 mg of NET, 5 alpha-NET or 3 beta, 5 alpha-NET. Four hours later, they were sacrificed and blood obtained for the measurement of immunoreactive serum LH and FSH. The results indicated that antiestrogen (Tam) pretreatment precluded the inhibitory effects of NET and the 3 beta, 5 alpha-NET but not those of the 5 alpha-NET derivative. Pretreatment with CPA did not modified the antigonadotropic action of the 3 beta, 5 alpha-NET metabolite but it markedly reduced the inhibitory action of the 5 alpha-NET, thus indicating that in the experimental model used, the antigonadotropic effects of NET, are in part the result of its metabolic conversion to its A-ring reduced metabolites. While the 5 alpha-NET displayed an androgenic effect, the 3 beta, 5 alpha-NET exhibited estrogen-like effect at the neuroendocrine level.
Assuntos
Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Noretindrona/farmacologia , Animais , Ciproterona/análogos & derivados , Ciproterona/farmacologia , Acetato de Ciproterona , Feminino , Hormônio Foliculoestimulante/sangue , Hormônio Luteinizante/sangue , Masculino , Noretindrona/análogos & derivados , Orquiectomia , Ovariectomia , Ratos , Ratos Endogâmicos , Relação Estrutura-Atividade , Tamoxifeno/farmacologiaRESUMO
The procedures for a systematic evaluation of the quality control of radioimmunoassay in general were described previously. In this report we present the parameters of quality control and their application to the radioimmunoassay (RIA) of pituitary gonadotrophic hormones, luteinizing hormone (LH) and follicle stimulating hormone (FSH) in serum. We present the results obtained in the intra-assay variation for the measurement of the pituitary gonadotrophic hormones in serum (LH and FSH) from 1983 to 1989. The results on bias and the inter-laboratory assessment through an external quality control scheme during the same period are also presented.